SEATTLE, April 25 /PRNewswire-FirstCall/ -- VentriPoint(TM) Diagnostics Ltd. today announced that it has finalized a research and technology development agreement with the University of Washington to collaborate on projects that will enhance and broaden the VentriPoint Diagnostic System (VDS) commercial offering.
Under the terms of the agreement, the University of Washington will expand its recruitment of leading institutions world-wide to participate in building comprehensive databases of right and left ventricle reconstructions representing specific heart diseases, such as congenital heart disease (CHD). These databases will be referenced by the VDS as it delivers three-dimensional models and analysis of patients’ hearts based on anatomical points identified by doctors on two-dimensional scans.
“Our core technology was first developed at the University of Washington, so it makes sense to collaborate with their subject matter experts,” said Joseph Ashley, CEO of VentriPoint Diagnostics. “The results of these projects will enhance and speed the commercial development of the VentriPoint Diagnostic System, which uses existing medical imaging systems to generate critical heart measurements in a rapid and inexpensive manner not currently available.”
Under the agreement, the University of Washington will collaborate with VentriPoint to increase the size of the database used by the VDS by up to 160 additional CHD heart reconstructions of different conditions. The University of Washington will also continue its transition of knowledge and processes to VentriPoint, in support of the technology license. It will also commence recruitment of patients with pulmonary hypertension to begin development of a subsequent VDS application. Financial terms of the agreement were not disclosed.
About VentriPoint Diagnostics
VentriPoint creates diagnostic tools to monitor patients with heart disease -- the number one cause of death in developed countries. By using existing medical imaging systems, the VentriPoint Diagnostic System generates critical heart measurements in a rapid and inexpensive manner not currently available. This breakthrough diagnostic tool is based upon VentriPoint’s technology license with the University of Washington. The VentriPoint Diagnostic System, together with its associated online service, is being developed for a variety of heart related disease states, including congenital heart disease.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
CONTACT: Edward Garth, Chief Financial Officer, VentriPoint Diagnostics
Ltd., +1-206-283-0221, ext. 402, fax +1-206-283-2309; or Media, Ian Stone
of Russo Partners LLC, +1-619-814-3510, ian.stone@russopartnersllc.com
